不可切除或转移性尿路上皮癌基因组检测实施的Delphi共识
该英国改良Delphi共识旨在建立不可切除或转移性尿路上皮癌(mUC)的标准化基因组检测路径,明确多学科团队(MDT)与分子病理实验室的职责。50份回复中41/42条陈述达成共识(≥75%同意),提出优先在启动一线系统治疗时进行FGFR3检测,并根据组织量和新鲜度选择标本。
要点
- 推荐在启动一线系统治疗时优先进行FGFR3检测。
- 标本选择应基于组织量和新鲜度。
- MDT所有成员应能即时访问基因组检测报告。
核心结论
- 采用该Delphi共识衍生的基因组检测路径可明确MDT与分子实验室职责,减少区域获取差异,并通过及时检测和后续治疗优化患者结局。
研究设计与样本
- 采用改良Delphi法,由6名尿路上皮癌领域医疗专业人员组成指导委员会于2025年5月开会,制定7个共识主题并形成42条陈述。
- 通过在线4点Likert量表调查临床科学家和医疗专业人员,共收到50份回复,预设共识标准为≥75%同意。
主要发现
- 50份回复中,41/42条陈述达成共识,未达成共识的陈述属于一对配对陈述之一。
- 基于调查结果和指导委员会讨论,制定了不可切除或mUC的预检测和基因组检测路径。
关键数值与推荐
- 共识预定义为≥75%同意;共41/42条陈述达到该阈值。
- 路径关键优先事项包括:及时进行FGFR3检测,理想情况在启动一线系统治疗时;根据组织量和新鲜度选择标本;MDT所有成员即时访问基因组检测报告;安全数据环境与联邦访问基因组结果。
临床怎么用
- 临床应采用该共识路径以明确MDT和分子实验室在基因组检测中的职责,减少区域间获取差异。
- 应在启动一线系统治疗时优先安排FGFR3检测,并确保MDT成员能即时获取检测报告以指导治疗决策。
局限性
- 共识基于50份回复的在线调查,未达成共识的陈述属于配对陈述之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To establish a UK consensus vision of a standardised genomic testing pathway in unresectable/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations. SUBJECTS AND METHODS: A modified Delphi method was used. Six healthcare professionals (HCPs) with expertise in UC formed the Steering Committee (SC), which met in May 2025. Seven key consensus topics were developed covering the steps of the pre-testing and genomic testing pathways, the current and future state of precision medicine, and approaches to overcome barriers and ensure readiness for the future. Within these topics, statements were developed and distributed to clinical scientists and HCPs via an on-line 4-point Likert scale survey. Respondents could opt out of responding to statements outside their area of expertise. Consensus was pre-defined as ≥75% agreement. RESULTS: Overall, 50 responses were received; consensus was reached on 41/42 statements. The statement that did not achieve consensus was part of a paired set. A proposed pathway for pre-testing and genomic testing in unresectable or mUC was developed based on survey results and discussions at SC meetings. Key priorities for the pathway include: timely fibroblast growth factor receptor 3 testing, ideally at the commencement of first-line systemic therapies; selection of specimens based on volume of tissue and recency; immediate access to the genomic testing report for all MDT members; and secure data environments with federated access to genomic results. Since the stopping criteria were met, no further survey rounds were required. CONCLUSION: Adopting the genomic testing pathway derived from this Delphi consensus will provide greater clarity around MDT and molecular laboratory responsibilities, reduce regional inequities in access, and optimise patient outcomes through timely delivery of genomic testing and subsequent treatment.
引用
- Hussain SA, Challapalli A, Gill S, et al. A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer. BJU Int. 2026. PMID: 42037417. doi:10.1111/bju.70278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。